Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.
Breast Cancer Research : Bcr
Miyashita, Minoru M; Bell, Joshua S K JSK; Wenric, Stephane S; Karaesmen, Ezgi E; Rhead, Brooke B; Kase, Matthew M; Kaneva, Kristiyana K; De La Vega, Francisco M FM; Zheng, Yonglan Y; Yoshimatsu, Toshio F TF; Khramtsova, Galina G; Liu, Fang F; Zhao, Fangyuan F; Howard, Frederick M FM; Nanda, Rita R; Beaubier, Nike N; White, Kevin P KP; Huo, Dezheng D; Olopade, Olufunmilayo I OI
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.
Breast Cancer Research And Treatment
Bos, M K MK; Lam, S W SW; Motta, G G; Helmijr, J C A JCA; Beaufort, C M CM; de Jonge, E E; Martens, J W M JWM; Boven, E E; Jansen, M P H M MPHM; Jager, A A; Sleijfer, S S
Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2).
Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value.
British Journal Of Cancer
Franken, André A; Kraemer, Annika A; Sicking, Alicia A; Watolla, Meike M; Rivandi, Mahdi M; Yang, Liwen L; Warfsmann, Jens J; Polzer, Bernhard M BM; Friedl, Thomas W P TWP; Meier-Stiegen, Franziska F; Stoecklein, Nikolas H NH; Dayan, Davut D; Riethdorf, Sabine S; Mueller, Volkmar V; Pantel, Klaus K; Koch, André A; Hartkopf, Andreas D AD; Krawczyk, Natalia N; Ruckhaeberle, Eugen E; Niederacher, Dieter D; Fehm, Tanja T; Neubauer, Hans H
EstroGene database reveals diverse temporal, context-dependent and directional estrogen receptor regulomes in breast cancer.
Biorxiv : The Preprint Server For Biology
Li, Zheqi Z; Li, Tianqin T; Yates, Megan E ME; Wu, Yang Y; Ferber, Amanda A; Chen, Lyuqin L; Brown, Daniel D DD; Carroll, Jason S JS; Sikora, Matthew J MJ; Tseng, George C GC; Oesterreich, Steffi S; Lee, Adrian V AV
Towards precision radiation oncology: endocrine therapy response as a biomarker for personalization of breast radiotherapy.
Npj Precision Oncology
Udden, S M Nashir SMN; Baek, GuemHee G; Pandey, Kamal K; Vidal, Chantal C; Liu, Yulun Y; Rahimi, Asal S AS; Kim, D Nathan DN; Nwachukwu, Chika R CR; Mani, Ram S RS; Alluri, Prasanna G PG
Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer.
Clinical Cancer Research : An Official Journal Of The American Association For Cancer Research
Davis, Andrew A AA; Luo, Jingqin J; Zheng, Tiantian T; Dai, Chao C; Dong, Xiaoxi X; Tan, Lu L; Suresh, Rama R; Ademuyiwa, Foluso O FO; Rigden, Caron C; Rearden, Timothy P TP; Clifton, Katherine K; Weilbaecher, Katherine K; Frith, Ashley A; Tandra, Pavankumar K PK; Summa, Tracy T; Haas, Brittney B; Thomas, Shana S; Hernandez-Aya, Leonel F LF; Peterson, Lindsay L LL; Wang, Xiaohong X; Luo, Shujun J SJ; Zhou, Kemin K; Du, Pan P; Jia, Shidong S; King, Bonnie L BL; Krishnamurthy, Jairam J; Ma, Cynthia X CX
Publication Date: 2023-01-24
Variant appearance in text: ESR1: 1610A>C; Tyr537Ser
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancer.
Nature Communications
Sivakumar, Smruthy S; Jin, Dexter X DX; Tukachinsky, Hanna H; Murugesan, Karthikeyan K; McGregor, Kimberly K; Danziger, Natalie N; Pavlick, Dean D; Gjoerup, Ole O; Ross, Jeffrey S JS; Harmon, Robert R; Chung, Jon J; Decker, Brennan B; Dennis, Lucas L; Frampton, Garrett M GM; Molinero, Luciana L; Oesterreich, Steffi S; Venstrom, Jeffrey M JM; Oxnard, Geoffrey R GR; Hegde, Priti S PS; Sokol, Ethan S ES
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.
Npj Breast Cancer
Pancholi, Sunil S; Simigdala, Nikiana N; Ribas, Ricardo R; Schuster, Eugene E; Leal, Mariana Ferreira MF; Nikitorowicz-Buniak, Joanna J; Rega, Camilla C; Bihani, Teeru T; Patel, Hitisha H; Johnston, Stephen R SR; Dowsett, Mitch M; Martin, Lesley-Ann LA
Author Correction: High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Nature Communications
Palafox, Marta M; Monserrat, Laia L; Bellet, Meritxell M; Villacampa, Guillermo G; Gonzalez-Perez, Abel A; Oliveira, Mafalda M; Brasó-Maristany, Fara F; Ibrahimi, Nusaibah N; Kannan, Srinivasaraghavan S; Mina, Leonardo L; Herrera-Abreu, Maria Teresa MT; Òdena, Andreu A; Sánchez-Guixé, Mònica M; Capelán, Marta M; Azaro, Analía A; Bruna, Alejandra A; Rodríguez, Olga O; Guzmán, Marta M; Grueso, Judit J; Viaplana, Cristina C; Hernández, Javier J; Su, Faye F; Lin, Kui K; Clarke, Robert B RB; Caldas, Carlos C; Arribas, Joaquín J; Michiels, Stefan S; García-Sanz, Alicia A; Turner, Nicholas C NC; Prat, Aleix A; Nuciforo, Paolo P; Dienstmann, Rodrigo R; Verma, Chandra S CS; Lopez-Bigas, Nuria N; Scaltriti, Maurizio M; Arnedos, Monica M; Saura, Cristina C; Serra, Violeta V
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer.
Oncogene
Harrod, Alison A; Lai, Chun-Fui CF; Goldsbrough, Isabella I; Simmons, Georgia M GM; Oppermans, Natasha N; Santos, Daniela B DB; Győrffy, Balazs B; Allsopp, Rebecca C RC; Toghill, Bradley J BJ; Balachandran, Kirsty K; Lawson, Mandy M; Morrow, Christopher J CJ; Surakala, Manasa M; Carnevalli, Larissa S LS; Zhang, Pei P; Guttery, David S DS; Shaw, Jacqueline A JA; Coombes, R Charles RC; Buluwela, Lakjaya L; Ali, Simak S